SG10201606990TA - Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives - Google Patents

Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives

Info

Publication number
SG10201606990TA
SG10201606990TA SG10201606990TA SG10201606990TA SG10201606990TA SG 10201606990T A SG10201606990T A SG 10201606990TA SG 10201606990T A SG10201606990T A SG 10201606990TA SG 10201606990T A SG10201606990T A SG 10201606990TA SG 10201606990T A SG10201606990T A SG 10201606990TA
Authority
SG
Singapore
Prior art keywords
protein
aggregates
treatment
methods
organic additives
Prior art date
Application number
SG10201606990TA
Inventor
Peter Gagnon
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG10201606990TA publication Critical patent/SG10201606990TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG10201606990TA 2012-05-31 2013-02-06 Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives SG10201606990TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261653752P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
SG10201606990TA true SG10201606990TA (en) 2016-10-28

Family

ID=49673721

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407812SA SG11201407812SA (en) 2012-05-31 2013-02-06 Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
SG10201606990TA SG10201606990TA (en) 2012-05-31 2013-02-06 Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201407812SA SG11201407812SA (en) 2012-05-31 2013-02-06 Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives

Country Status (8)

Country Link
US (1) US10246506B2 (en)
EP (1) EP2855502B1 (en)
JP (2) JP2015519361A (en)
KR (1) KR102067445B1 (en)
CN (1) CN104507953B (en)
IN (1) IN2014DN09948A (en)
SG (2) SG11201407812SA (en)
WO (1) WO2013180650A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014123484A1 (en) * 2013-02-06 2014-08-14 Agency For Science, Technology And Research Methods For Reducing Aggregate Content In Protein Preparations
SG10201610955SA (en) * 2013-02-26 2017-02-27 Agency Science Tech & Res Protein purification in the presence of nonionic organic polymers and electropositive surfaces
CN105008384A (en) * 2013-02-28 2015-10-28 新加坡科技研究局 Protein purification in the presence of nonionic organic polymers at elevated conductivity
JP2017507149A (en) 2014-02-27 2017-03-16 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ Antibody purification method
EP3116892A4 (en) * 2014-02-27 2017-11-22 Agency For Science, Technology And Research Methods for reducing aggregate content of protein preparations by treatment with aryl anions
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
EP3442988A4 (en) * 2016-06-15 2020-02-26 Agency for Science, Technology and Research A method of enhancing the performance of chromatography methods for purification of proteins
KR20190027878A (en) 2016-07-13 2019-03-15 리폼 바이오로직스, 엘엘씨 Stabilizing excipients for therapeutic protein preparations
DE102016010601B4 (en) 2016-09-01 2018-11-08 Sartorius Stedim Biotech Gmbh A process for the purification of viruses or virus-like particles using a crosslinked cellulose hydrate membrane
WO2019036619A1 (en) * 2017-08-18 2019-02-21 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
CN113493570B (en) * 2020-04-01 2022-11-01 中国科学院理化技术研究所 Method for reducing endotoxin in gelatin by adopting allantoin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
AU597924B2 (en) * 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
DK0671905T3 (en) * 1993-10-06 2002-10-07 Amgen Inc Stable protein: pholipid compositions and methods
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
SE9500778D0 (en) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE0201257D0 (en) * 2002-04-25 2002-04-25 Medical Invest In Sweden Ab Improved Separation
CN1286453C (en) * 2003-07-25 2006-11-29 复旦大学 Method for stablizing protein medicine and its application in microball preparation
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
EP2195330B1 (en) * 2007-10-12 2013-03-13 Merck Patent GmbH Method and agent for refolding proteins
CN102119168A (en) * 2008-06-03 2011-07-06 帕特里有限公司 Process for purification of antibodies
EP2241886A1 (en) * 2009-04-15 2010-10-20 Beckman Coulter Biomedical Limited Homogeneous agglutination immunoassay method and kit for such method
US9193760B2 (en) * 2010-09-20 2015-11-24 Bio-Rad Laboratories, Inc. Dissociation of product-complexed contaminants in chromatography
CN104487446B (en) * 2012-05-31 2018-05-29 新加坡科技研究局 The method for reducing aggregation content in protein formulation using the multi-functional surface of mixing
JP6297029B2 (en) * 2012-05-31 2018-03-20 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ Chromatographic purification of immunoglobulin G preparations with particles having various functional groups
JP6200949B2 (en) * 2012-05-31 2017-09-20 エイジェンシー フォー サイエンス，テクノロジー アンド リサーチ Selective binding of biological targets to solid phase ureides

Also Published As

Publication number Publication date
IN2014DN09948A (en) 2015-08-14
US10246506B2 (en) 2019-04-02
SG11201407812SA (en) 2014-12-30
CN104507953B (en) 2018-05-18
EP2855502B1 (en) 2019-06-26
KR102067445B1 (en) 2020-01-17
JP2017222699A (en) 2017-12-21
CN104507953A (en) 2015-04-08
EP2855502A4 (en) 2016-02-17
JP2015519361A (en) 2015-07-09
KR20150028231A (en) 2015-03-13
JP6491277B2 (en) 2019-03-27
EP2855502A1 (en) 2015-04-08
WO2013180650A1 (en) 2013-12-05
US20150148526A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
SG10201606990TA (en) Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
RS59211B1 (en) Antifungal topical composition and methods of treatment
SG10201706205RA (en) Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations
HK1201543A1 (en) Method for treating clay and clay-bearing aggregates and compositions therefor
EP2863920A4 (en) Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP3049536A4 (en) Methods and compositions relating to cancer therapy with dna damaging agents
DK3292875T3 (en) Compositions and methods for treating diseases
HK1224184A1 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EP2855503A4 (en) Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations
EP3003290A4 (en) Compositions and methods for induced tissue regeneration in mammalian species
IL236637A (en) Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
SG10201710538XA (en) Compositions and methods for treating skin
EP2968374A4 (en) Methods and compositions for enhancing oxygen levels in tissues
EP2922544A4 (en) Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
EP2956469A4 (en) Methods and compositions for protein concentration
EP2928460A4 (en) Methods for preventing and treating inflammatory skin conditions
EP2683386A4 (en) Compounds and methods of use in ablative radiotherapy
RS61101B1 (en) Compositions and methods for treating cutaneous t cell lymphoma
GB2501806B (en) Improvements in Treatment of Exhaust Emissions
GB2558442B (en) Antibodies for use in treating conditions related to specific PCSK9 variants and associated diagnostic methods
GB201306744D0 (en) Improvements in and relating to gate assemblies
AU2013904530A0 (en) Methods and apparatuses for improving peripheral activity in computing devices